Roche's atezolizumab seen as driver of bladder cancer treatment market

29 July 2015
2019_biotech_test_vial_discovery_big

Swiss pharma giant Roche’s (ROG: SIX) atezolizumab is poised to become a major bladder cancer therapy in the race for US Food & Drug Administration approval, following its promising performance in recent Phase II trials, says an analyst with research and consulting firm GlobalData.

In a potential bladder cancer breakthrough, Roche announced that atezolizumab, an anti-Programmed Death-Ligand 1 (PD-L1) therapy, met its primary endpoint of objective response rate in the  Phase II IMvigor 210 study. During the trial, patients with higher PD-L1 expression levels showed better responses to the drug.

According to Cai Xuan, GlobalData's analyst covering oncology and hematology, this observation, along with similar results for other Programmed Cell Death Protein 1 (PD-1) inhibitors in development for various cancers, opens up a market for companion biomarker tests that can be used to identify patients who would likely benefit from PD-1/PD-L1-targeted therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology